Rapport Therapeutics (NASDAQ:RAPP) just reported results for the second quarter of 2024.
- Rapport Therapeutics reported earnings per share of -$1.70. This was below the analyst estimate for EPS of -67 cents.
- The company did not report any revenue for the quarter.